CA2425368C - New sulphoxybenzamides - Google Patents

New sulphoxybenzamides Download PDF

Info

Publication number
CA2425368C
CA2425368C CA002425368A CA2425368A CA2425368C CA 2425368 C CA2425368 C CA 2425368C CA 002425368 A CA002425368 A CA 002425368A CA 2425368 A CA2425368 A CA 2425368A CA 2425368 C CA2425368 C CA 2425368C
Authority
CA
Canada
Prior art keywords
denote
independently
another
group
denotes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002425368A
Other languages
English (en)
French (fr)
Other versions
CA2425368A1 (en
Inventor
Ralf Anderskewitz
Kurt Schromm
Franz Birke
Hans Michael Jennewein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Publication of CA2425368A1 publication Critical patent/CA2425368A1/en
Application granted granted Critical
Publication of CA2425368C publication Critical patent/CA2425368C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C305/00—Esters of sulfuric acids
    • C07C305/22—Esters of sulfuric acids having oxygen atoms of sulfate groups bound to carbon atoms of six-membered aromatic rings
    • C07C305/24—Esters of sulfuric acids having oxygen atoms of sulfate groups bound to carbon atoms of six-membered aromatic rings of non-condensed six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CA002425368A 2000-10-24 2001-10-19 New sulphoxybenzamides Expired - Fee Related CA2425368C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10052333A DE10052333A1 (de) 2000-10-24 2000-10-24 Neue Sulfooxybenzamide
DE10052333.1 2000-10-24
PCT/EP2001/012127 WO2002034715A1 (de) 2000-10-24 2001-10-19 Benzamidin-derivate mit einer sulfat-gruppe als ltb4-antagonisten

Publications (2)

Publication Number Publication Date
CA2425368A1 CA2425368A1 (en) 2003-04-08
CA2425368C true CA2425368C (en) 2008-12-09

Family

ID=7660637

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002425368A Expired - Fee Related CA2425368C (en) 2000-10-24 2001-10-19 New sulphoxybenzamides

Country Status (8)

Country Link
EP (1) EP1332128A1 (es)
JP (1) JP3917516B2 (es)
AU (1) AU2002210558A1 (es)
CA (1) CA2425368C (es)
DE (1) DE10052333A1 (es)
MX (1) MXPA03003465A (es)
PE (1) PE20020542A1 (es)
WO (1) WO2002034715A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3983272B2 (ja) * 2004-07-14 2007-09-26 有限会社 炎症研究所 腫瘍転移の抑制方法
EP1792623B1 (en) * 2005-07-08 2010-03-10 Leopold-Franzens-Universität Innsbruck Use of extracts and constituents of leontopodium as enhancers of cholinergic function
CN100402494C (zh) * 2005-08-25 2008-07-16 江苏吴中苏药医药开发有限责任公司 肌醇硫酸酯铝及其制备方法和口服组合物、应用
EA024381B1 (ru) 2011-03-16 2016-09-30 Криэйтив Терапьютикс Гмбх Замещенные дифенильные производные
JP7373191B2 (ja) 2017-05-12 2023-11-02 国立研究開発法人理化学研究所 クラスａ ｇｐｃｒ結合性化合物改変体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU673343B2 (en) * 1992-02-05 1996-11-07 Boehringer Ingelheim International Gmbh Novel amidine derivatives, their preparation and their use as mediaments with LTB4 antagonistic effect
DE19546452A1 (de) * 1995-12-13 1997-06-19 Boehringer Ingelheim Kg Neue Phenylamidinderivate, Verfahren zu ihrer Herstelung und ihre Verwendung als Arzneimittel
DE19636689A1 (de) * 1996-09-10 1998-03-12 Boehringer Ingelheim Kg Neue Benzamidinderivate

Also Published As

Publication number Publication date
WO2002034715A1 (de) 2002-05-02
JP3917516B2 (ja) 2007-05-23
CA2425368A1 (en) 2003-04-08
JP2004512322A (ja) 2004-04-22
DE10052333A1 (de) 2002-05-02
EP1332128A1 (de) 2003-08-06
MXPA03003465A (es) 2004-12-06
PE20020542A1 (es) 2002-07-16
AU2002210558A1 (en) 2002-05-06

Similar Documents

Publication Publication Date Title
JP4288299B2 (ja) Ｌｔｂ４−アンタゴニスト活性を有するベンズアミジン誘導体及びその医薬としての使用
EA028378B1 (ru) Дейтерированные производные ивакафтора
HU224823B1 (en) Substituted benzamidines,process for preparing the said compds. and pharmaceutical compns. contg. them
US7141595B2 (en) Amino benzothiazole compounds with NOS inhibitory activity
US5686496A (en) Chemical compound, the preparation thereof and its use in pharmaceutical compositions
KR100293867B1 (ko) 아미노스틸바졸유도체및의약
JPH03505728A (ja) 合成方法および薬剤用新規化合物
US6335338B1 (en) Calcilytic compounds
CA2425368C (en) New sulphoxybenzamides
EP0306827B1 (en) Amide compounds, process for preparing the same, and composition for activating gastric motor function containing the same
US4413011A (en) Substituted 2,2-dimethyl-5-phenoxypentanoic acid benzamides as anti-arteriosclerotic agents and method
US6291459B1 (en) Calcilytic compounds
US6489359B2 (en) Sulphoxybenzamides
US8871764B2 (en) Lisofylline analogs and methods for use
US6291531B1 (en) LTB4 antagonist, processes for the preparation thereof and its use as a pharmaceutical composition
US4882357A (en) Novel N-(substituted-phenyl)-5-(substituted-2,5-dimethylphenoxy)-2,2-dimethylpentanamides
US7470788B2 (en) Antitumor agents
EP0335408A2 (en) Substituted benzene derivatives, processes for their production and antitumour compositions containing them
US20060167003A1 (en) Probucol derivatives
US5326870A (en) Substituted sulfonamide derivative and a pharmaceutical composition comprising the same
US4554282A (en) Substituted 2,2-dimethyl-5-phenoxypentanoic acid benzamides as anti-arteriosclerotic agents and method
JPS6270335A (ja) ２環性アリルエ−テル誘導体、その製法および用途
US6528491B2 (en) Pyranoside derivatives
CA2385871C (en) Ltb4 antagonist, processes for the preparation thereof and its use as a pharmaceutical composition
CA2426564A1 (en) Pyranoside derivatives

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed